Regional citrate anticoagulation for continuous renal replacement therapy

Current Opinion in Critical Care - Tập 24 Số 6 - Trang 450-454 - 2018
Detlef Kindgen‐Milles1, Timo Brandenburger, Thomas Dimski
1Department of Anesthesiology, University Hospital Duesseldorf, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.

Tóm tắt

Purpose of review The delivery of an effective dialysis dose in continuous renal replacement therapy (CRRT) depends on adequate anticoagulation of the extracorporeal circuit. In most patients, either systemic heparin anticoagulation (SHA) or regional citrate anticoagulation (RCA) is used. This review will outline the basics and rationale of RCA and summarize data on safety and efficacy of both techniques. Recent findings The basic principle of RCA is to reduce the level of ionized calcium in the extracorporeal circuit via infusion of citrate. This way, effective anticoagulation restricted to the extracorporeal circuit is achieved. SHA and RCA were compared in a variety of studies. RCA significantly prolonged filter lifetime, reduced bleeding complications and provided excellent control of uremia and acid-base status. RCA was also safe in the majority of patients with impaired liver function, whereas caution must be exerted in those with severe multiorgan failure and persistent hyperlactatemia. Summary RCA per se is safe and effective for anticoagulation of CRRT. Compared to SHA, efficacy of anticoagulation is improved and adverse effects are reduced. RCA can be recommended as the anticoagulation mode of choice for CRRT in most ICU patients.

Từ khóa


Tài liệu tham khảo

van de Wetering, 1996, Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage, J Am Soc Nephrol, 7, 145, 10.1681/ASN.V71145

MacEwen, 2015, Circuit life versus bleeding risk: the impact of achieved activated partial thromboplastin time versus achieved filtration fraction, Ther Apher Dial, 19, 259, 10.1111/1744-9987.12253

Brandenburger, 2017, Renal replacement therapy and anticoagulation, Best Pract Res Clin Anaesthesiol, 31, 387, 10.1016/j.bpa.2017.08.005

Monchi, 2017, Citrate pathophysiology and metabolism, Transfus Apher Sci, 56, 28, 10.1016/j.transci.2016.12.013

Mehta, 1990, Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients, Kidney Int, 38, 976, 10.1038/ki.1990.300

Morgera, 2009, A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status, Crit Care Med, 37, 2018, 10.1097/CCM.0b013e3181a00a92

Hetzel, 2006, Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration, Am J Kidney Dis, 48, 806, 10.1053/j.ajkd.2006.07.016

Durao, 2008, The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury, Crit Care Med, 36, 3024, 10.1097/CCM.0b013e31818b9100

Bai, 2015, Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs, Intensive Care Med, 41, 2098, 10.1007/s00134-015-4099-0

Slowinski, 2015, Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study, Crit Care, 19, 349, 10.1186/s13054-015-1066-7

Oudemans-van Straaten, 2009, Citrate anticoagulation for continuous venovenous hemofiltration, Crit Care Med, 37, 545, 10.1097/CCM.0b013e3181953c5e

2012, KDIGO Clinical Practice Guideline for Acute Kidney Injury, Kidney Int, 2, 1

Monchi, 2004, Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study, Intensive Care Med, 30, 260, 10.1007/s00134-003-2047-x

Oudemans-van Straaten, 2010, Citrate anticoagulation for continuous renal replacement therapy in the critically ill, Blood Purif, 29, 191, 10.1159/000245646

Liu, 2016, Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials, Crit Care, 20, 144, 10.1186/s13054-016-1299-0

Kalb, 2013, Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk, Ther Apher Dial, 17, 202, 10.1111/j.1744-9987.2012.01101.x

Park, 2011, Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration, Korean J Intern Med, 26, 68, 10.3904/kjim.2011.26.1.68

Morabito, 2012, Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution, Crit Care, 16, R111, 10.1186/cc11403

Shum, 2012, Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocitrate 10/2 solution, Ther Apher Dial, 16, 81, 10.1111/j.1744-9987.2011.01001.x

Jacobs, 2016, Regional citrate anticoagulation for continuous renal replacement therapy: all citrates are not created equal!, Blood Purif, 42, 219, 10.1159/000448801

Zhang, 2012, Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy, Intensive Care Med, 38, 20, 10.1007/s00134-011-2438-3

Klingele, 2014, The gap between calculated and actual calcium substitution during citrate anticoagulation in an immobilised patient on renal replacement therapy reflects the extent of bone loss: a case report, BMC Nephrol, 15, 163, 10.1186/1471-2369-15-163

Raimundo, 2013, Maintaining normal levels of ionized calcium during citrate-based renal replacement therapy is associated with stable parathyroid hormone levels, Nephron Clin Pract, 124, 124, 10.1159/000355860

Khadzhynov, 2017, Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation, Crit Care Med, 45, e941, 10.1097/CCM.0000000000002501

Schultheiss, 2012, Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study, Crit Care, 16, R162, 10.1186/cc11485

Kramer, 2003, Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients, Crit Care Med, 31, 2450, 10.1097/01.CCM.0000084871.76568.E6

Meier-Kriesche, 2001, Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation, Crit Care Med, 29, 748, 10.1097/00003246-200104000-00010

Balogun, 2012, Regional citrate anticoagulation in critically ill patients with liver and kidney failure, J Nephrol, 25, 113, 10.5301/JN.2011.8363

Saner, 2012, Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring postoperative renal replacement therapy, Nephrol Dial Transplant, 27, 1651, 10.1093/ndt/gfr510

Faybik, 2011, Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system, Crit Care Med, 39, 273, 10.1097/CCM.0b013e3181fee8a4

Senturk, 2010, The treatment of acute liver failure with fractionated plasma separation and adsorption system: experience in 85 applications, J Clin Apher, 25, 195, 10.1002/jca.20238

Thông tin
Thông tin xuất bản

Current Opinion in Critical Care

Tập 24 Số 6

450-454

Thông tin tác giả